EKSO Relative Valuation
EKSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EKSO is overvalued; if below, it's undervalued.
Historical Valuation
Ekso Bionics Holdings Inc (EKSO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.32 is considered Overvalued compared with the five-year average of -3.10. The fair price of Ekso Bionics Holdings Inc (EKSO) is between 6.04 to 7.89 according to relative valuation methord. Compared to the current price of 8.82 USD , Ekso Bionics Holdings Inc is Overvalued By 11.75%.
Relative Value
Fair Zone
6.04-7.89
Current Price：8.82
11.75%
Overvalued
-7.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Ekso Bionics Holdings Inc. (EKSO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.52. The thresholds are as follows: Strongly Undervalued below -5.27, Undervalued between -5.27 and -2.89, Fairly Valued between 1.86 and -2.89, Overvalued between 1.86 and 4.24, and Strongly Overvalued above 4.24. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-6.69
EV/EBIT
Ekso Bionics Holdings Inc. (EKSO) has a current EV/EBIT of -6.69. The 5-year average EV/EBIT is -1.52. The thresholds are as follows: Strongly Undervalued below -5.39, Undervalued between -5.39 and -3.45, Fairly Valued between 0.42 and -3.45, Overvalued between 0.42 and 2.36, and Strongly Overvalued above 2.36. The current Forward EV/EBIT of -6.69 falls within the Strongly Undervalued range.
1.32
PS
Ekso Bionics Holdings Inc. (EKSO) has a current PS of 1.32. The 5-year average PS is 2.02. The thresholds are as follows: Strongly Undervalued below -2.35, Undervalued between -2.35 and -0.17, Fairly Valued between 4.21 and -0.17, Overvalued between 4.21 and 6.39, and Strongly Overvalued above 6.39. The current Forward PS of 1.32 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Ekso Bionics Holdings Inc. (EKSO) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.23. The thresholds are as follows: Strongly Undervalued below -2.97, Undervalued between -2.97 and -1.60, Fairly Valued between 1.15 and -1.60, Overvalued between 1.15 and 2.52, and Strongly Overvalued above 2.52. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Ekso Bionics Holdings Inc. (EKSO) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.18. The thresholds are as follows: Strongly Undervalued below -2.94, Undervalued between -2.94 and -1.56, Fairly Valued between 1.20 and -1.56, Overvalued between 1.20 and 2.57, and Strongly Overvalued above 2.57. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Ekso Bionics Holdings Inc (EKSO) has a current Price-to-Book (P/B) ratio of 2.12. Compared to its 3-year average P/B ratio of 1.21 , the current P/B ratio is approximately 75.83% higher. Relative to its 5-year average P/B ratio of 1.80, the current P/B ratio is about 18.12% higher. Ekso Bionics Holdings Inc (EKSO) has a Forward Free Cash Flow (FCF) yield of approximately -33.78%. Compared to its 3-year average FCF yield of -72.94%, the current FCF yield is approximately -53.68% lower. Relative to its 5-year average FCF yield of -57.93% , the current FCF yield is about -41.68% lower.
2.12
P/B
Median3y
1.21
Median5y
1.80
-33.78
FCF Yield
Median3y
-72.94
Median5y
-57.93
Competitors Valuation Multiple
The average P/S ratio for EKSO's competitors is 2.56, providing a benchmark for relative valuation. Ekso Bionics Holdings Inc Corp (EKSO) exhibits a P/S ratio of 1.32, which is -48.24% above the industry average. Given its robust revenue growth of 2.37%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EKSO increased by 9.29% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.07 to -1.50.
The secondary factor is the Revenue Growth, contributed 2.37%to the performance.
Overall, the performance of EKSO in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
PRPH
Prophase Labs Inc
0.2USD
-23.44%
AQMS
Aqua Metals Inc
5.475USD
-1.17%
CWD
CaliberCos Inc
1.39USD
-0.71%
BOF
BranchOut Food Inc
3.15USD
0.64%
EDUC
Educational Development Corp
1.43USD
4.38%
PHGE
Biomx Inc
2.24USD
3.70%
NCI
Neo-Concept International Group Holdings Ltd
1.24USD
0.00%
TKLF
Tokyo Lifestyle Co Ltd
3.2USD
3.56%
DPRO
Draganfly Inc
9.37USD
13.03%
Frequently Asked Questions
Is Ekso Bionics Holdings Inc (EKSO) currently overvalued or undervalued?
Ekso Bionics Holdings Inc (EKSO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1.32 is considered Overvalued compared with the five-year average of -3.10. The fair price of Ekso Bionics Holdings Inc (EKSO) is between 6.04 to 7.89 according to relative valuation methord. Compared to the current price of 8.82 USD , Ekso Bionics Holdings Inc is Overvalued By 11.75% .
What is Ekso Bionics Holdings Inc (EKSO) fair value?
EKSO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ekso Bionics Holdings Inc (EKSO) is between 6.04 to 7.89 according to relative valuation methord.
How does EKSO's valuation metrics compare to the industry average?
The average P/S ratio for EKSO's competitors is 2.56, providing a benchmark for relative valuation. Ekso Bionics Holdings Inc Corp (EKSO) exhibits a P/S ratio of 1.32, which is -48.24% above the industry average. Given its robust revenue growth of 2.37%, this premium appears unsustainable.
What is the current P/B ratio for Ekso Bionics Holdings Inc (EKSO) as of Jan 08 2026?
As of Jan 08 2026, Ekso Bionics Holdings Inc (EKSO) has a P/B ratio of 2.12. This indicates that the market values EKSO at 2.12 times its book value.
What is the current FCF Yield for Ekso Bionics Holdings Inc (EKSO) as of Jan 08 2026?
As of Jan 08 2026, Ekso Bionics Holdings Inc (EKSO) has a FCF Yield of -33.78%. This means that for every dollar of Ekso Bionics Holdings Inc’s market capitalization, the company generates -33.78 cents in free cash flow.
What is the current Forward P/E ratio for Ekso Bionics Holdings Inc (EKSO) as of Jan 08 2026?
As of Jan 08 2026, Ekso Bionics Holdings Inc (EKSO) has a Forward P/E ratio of -7.00. This means the market is willing to pay $-7.00 for every dollar of Ekso Bionics Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Ekso Bionics Holdings Inc (EKSO) as of Jan 08 2026?
As of Jan 08 2026, Ekso Bionics Holdings Inc (EKSO) has a Forward P/S ratio of 1.32. This means the market is valuing EKSO at $1.32 for every dollar of expected revenue over the next 12 months.